NovoCure
NVCR
129 hedge funds and large institutions have $959M invested in NovoCure in 2018 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 41 increasing their positions, 46 reducing their positions, and 19 closing their positions.
686% more call options, than puts
Call options by funds: $32M | Put options by funds: $4.08M
23% more capital invested
Capital invested by funds: $778M → $959M (+$182M)
11% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 19
5.89% more ownership
Funds ownership: 43.07% → 48.97% (+5.9%)
1% more funds holding
Funds holding: 128 → 129 (+1)
11% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 46
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$46.1M |
| 2 |
Mitsubishi UFJ Trust & Banking
Tokyo,
Japan
|
+$18.3M |
| 3 |
PC
PointState Capital
New York
|
+$18.3M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$16.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$16.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.4M |
| 2 |
HCM
Highline Capital Management
New York
|
-$9.56M |
| 3 |
SG
StepStone Group
La Jolla,
California
|
-$5.38M |
| 4 |
Millennium Management
New York
|
-$5.1M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$3.51M |
NVCR Hedge Fund Activity: Q1 2018 in Review
129 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q1 2018, worth a combined $959M — up 23% from $778M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new NVCR positions and 19 closed out — a net gain of 2 holders — while 41 added to existing stakes and 46 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $46.1M. The largest seller was Fidelity Investments, cutting an estimated $23.4M.
- 129 institutional investors held NovoCure (NVCR) as of Q1 2018, up from 128 in Q4 2017.
- Funds reported $959M of NovoCure stock for Q1 2018, up 23% quarter-over-quarter.
- 21 funds opened new NovoCure positions in Q1 2018 and 19 closed out, a net change of +2 holders.
- The largest NovoCure buyer in Q1 2018 was Baillie Gifford & Co, an estimated $46.1M added.
- The largest NovoCure seller in Q1 2018 was Fidelity Investments, an estimated $23.4M sold.
Based on aggregated 13F filings for Q1 2018.